Drugs / Arnica Tincture
Arnica Tincture
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT06822478 | Mar 2026 → Dec 2029 expected | cutaneous leishmaniasis | Universidad de Antioquia | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05094908 Comparator | May 2023 → Nov 2024 overdue | cutaneous leishmaniasis | Universidad de Antioquia | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Arnica Tincture | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06822478 ↗ |
| Known as | ARNICA TINTURA Gehrlicher | “The research product is the commercial phytotherapeutic product ARNICA TINTURA Gehrlicher 100 mL manufactured by Gehrlicher Pharmazeutische Extrakte GmbH.” NCT05094908 ↗ |
| Known as | Arnika tinktur Gehrlicher (5249) | “Arnika tincture is a topical plant-based preparation legally authorized in Colombia and in the countries of the European community, the product of this study is Arnika tinktur...” NCT06822478 ↗1“the product of this study is Arnika tinktur Gehrlicher (5249), manufactured by Gehrlicher Pharmazeutische Extrakte GmbH, Germany.” NCT05094908 ↗ |
| Route | Topical | “Arnica tincture will be applied topically by each participant” NCT05094908 ↗ |